Media stories about Genetic Technologies (NASDAQ:GENE) have trended somewhat positive on Monday, according to Accern. The research group identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Genetic Technologies earned a coverage optimism score of 0.07 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 46.8440817310167 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Shares of Genetic Technologies (NASDAQ:GENE) traded up 2.38% on Monday, reaching $0.87. The company had a trading volume of 16,610 shares. Genetic Technologies has a 1-year low of $0.70 and a 1-year high of $2.89. The stock’s market capitalization is $14.12 million. The company’s 50 day moving average price is $0.81 and its 200-day moving average price is $0.97.

ILLEGAL ACTIVITY NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Genetic Technologies (GENE) Stock Price” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another publication, it was copied illegally and republished in violation of United States and international copyright and trademark legislation. The original version of this report can be read at

Genetic Technologies Company Profile

Genetic Technologies Limited is a molecular diagnostics company. The Company is engaged in the provision of molecular risk assessment for cancer. The Company offers predictive testing and assessment tools for physicians to manage women’s health. The Company’s lead product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer.

Insider Buying and Selling by Quarter for Genetic Technologies (NASDAQ:GENE)

Receive News & Stock Ratings for Genetic Technologies Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genetic Technologies Ltd and related stocks with our FREE daily email newsletter.